Business
Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies
Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies.
About this update from Biostax Corp.
[{"type":"text","content":"\nORLANDO, Fla., July 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) (\"Immune\" “IMUN” or the \"Company\"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, is pleased to announce the publication of a peer reviewed scientific paper describing LDN as a promising treatment in immune related disease and cancer therapies as identified in the lab by Dr. Fengping Shan, IMUN’s Chief Scientific Officer.\n The scientific paper by Fengping and Griffin et al. entitled, Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapies was recently published in the online edition of the International Immunopharmacology ( https://www.ncbi.nlm.nih.gov/pubmed/29885638) In this paper, the authors describe and analyze naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders. The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to opioid receptors in or on immune cells and tumor cells. These new discoveries indicate that LDN may become a promising immunomodulatory agent in the therapy for cancer and many immune-related diseases. In this article, we review the pharmacological functions and mechanisms of LDN as well as its clinical therapeutic potential as revealed by our team and other researchers. Until now, no review specific focused on the immunoregulatory functions of LDN has been reported. In this article, we provide a comprehensive summary of the immune-related pharmacological functions and potential mechanisms of LDN. To our knowledge, LDN could modulate the immune system function of the body to resist an abnormal immune response, and it has been widely accepted by patients with MS, IBD such as CD and many types of malignant...